IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
The Effect of the Nutraceutical "Hemofix" on the Coagulation System
This study has been withdrawn prior to enrollment.
Sponsor:
Hadassah Medical Organization
Collaborators:
HEMOFIX
Yocheved Grossman
Idan Grossman
Information provided by (Responsible Party):
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT01651468
First received: July 25, 2012
Last updated: February 22, 2017
Last verified: February 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Hemofix is a herbal formula based on traditional Jewish and far eastern medicine created to assist in wound healing and bleeding arrest. It contains herbs such as Red Clover, Liquorice, Raspberry, Ginger and more. The present study will evaluate the formula on the coagulation system.
| Condition | Intervention |
|---|---|
| Von Willebrand Disease Menorrhagia | Dietary Supplement: HEMOFIX |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: No masking Primary Purpose: Supportive Care |
| Official Title: | Phase 1 Study of the Nutraceutical "Hemofix" Safety and Effect on the Coagulation System |
Resource links provided by NLM:
Further study details as provided by Hadassah Medical Organization:
Primary Outcome Measures:
- bleeding and blood test results [ Time Frame: one year ]
| Enrollment: | 0 |
| Study Start Date: | September 2016 |
| Estimated Study Completion Date: | December 2023 |
| Estimated Primary Completion Date: | January 2020 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: HEMOFIX
3 grams a day
|
Dietary Supplement: HEMOFIX
unique complex herbal mixture
|
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Healthy volunteers and volunteers with a mild bleeding disorder
Exclusion Criteria:
- people with thrombophilic and cardiovascular complications,
- people who are treated with anti-coagulants,
- women taking birth control pills
- people with a history hypercoagulability
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01651468
Please refer to this study by its ClinicalTrials.gov identifier: NCT01651468
Locations
| Israel | |
| Hadassah Medical Organization | |
| Jerusalem, Israel | |
Sponsors and Collaborators
Hadassah Medical Organization
HEMOFIX
Yocheved Grossman
Idan Grossman
Investigators
| Principal Investigator: | David Varon, Prof | HMO |
More Information
| Responsible Party: | Hadassah Medical Organization |
| ClinicalTrials.gov Identifier: | NCT01651468 History of Changes |
| Other Study ID Numbers: |
HEMOFIX- HMO-CTIL |
| Study First Received: | July 25, 2012 |
| Last Updated: | February 22, 2017 |
Keywords provided by Hadassah Medical Organization:
|
mild bleeding disorder |
Additional relevant MeSH terms:
|
Menorrhagia Von Willebrand Diseases Uterine Hemorrhage Uterine Diseases Genital Diseases, Female Menstruation Disturbances Pathologic Processes |
Blood Coagulation Disorders, Inherited Blood Coagulation Disorders Hematologic Diseases Coagulation Protein Disorders Blood Platelet Disorders Hemorrhagic Disorders Genetic Diseases, Inborn |
ClinicalTrials.gov processed this record on July 19, 2017